CT-ADE: An Evaluation Benchmark for Adverse Drug Event Prediction from Clinical Trial Results
<|reference_start|>CT-ADE: An Evaluation Benchmark for Adverse Drug Event Prediction from Clinical Trial Results: Adverse drug events (ADEs) significantly impact clinical research, causing many clinical trial failures. ADE prediction is key for developing safer medications and enhancing patient outcomes. To support this effort, we introduce CT-ADE, a dataset for multilabel predictive modeling of ADEs in monopharmacy treatments. CT-ADE integrates data from 2,497 unique drugs, encompassing 168,984 drug-ADE pairs extracted from clinical trials, annotated with patient and contextual information, and comprehensive ADE concepts standardized across multiple levels of the MedDRA ontology. Preliminary analyses with large language models (LLMs) achieved F1-scores up to 55.90%. Models using patient and contextual information showed F1-score improvements of 21%-38% over models using only chemical structure data. Our results highlight the importance of target population and treatment regimens in the predictive modeling of ADEs, offering greater performance gains than LLM domain specialization and scaling. CT-ADE provides an essential tool for researchers aiming to leverage artificial intelligence and machine learning to enhance patient safety and minimize the impact of ADEs on pharmaceutical research and development. The dataset is publicly accessible at https://github.com/ds4dh/CT-ADE.<|reference_end|>
@article{yazdani2024ct-ade:,
    title={CT-ADE: An Evaluation Benchmark for Adverse Drug Event Prediction from
  Clinical Trial Results},
    author={Anthony Yazdani, Alban Bornet, Philipp Khlebnikov, Boya Zhang, Hossein
  Rouhizadeh, Poorya Amini and Douglas Teodoro},
    journal={arXiv preprint arXiv:2404.12827},
    year={2024},
    archivePrefix={arXiv},
    eprint={2404.12827},
    primaryClass={cs.CL}
}